London startup to trial drug preventing cytokine storm in cancer patients
Executive summary: Poolbeg Pharma is set to trial a drug in six NHS hospitals to prevent cytokine storm, a severe immune reaction, in cancer patients undergoing immunotherapy. If proven effective, the drug could reduce mortality and complications, lower treatment costs, and create a new market niche for adjunctive oncology therapies.
Who is involved: Poolbeg Pharma, NHS hospitals, cancer patients, oncology investors.
Likely next: Phase 1 safety data expected within months, followed by Phase 2 trials and regulatory review pending MHRA approval.
Poolbeg Pharma will begin a trial of a drug in six NHS hospitals that aims to prevent cytokine release syndrome, a life‑threatening side‑effect of cancer immunotherapy. The trial will assess safety and early efficacy in patients receiving checkpoint inhibitors. Success could introduce a new adjunct therapy and generate a new revenue stream for the startup.
Timeline
- — London startup to trial drug to prevent cancer therapy side-effect ‘cytokine storm’ (The Guardian — Business)
Analysis — what this means
Likely next events
- Phase 1 safety results in Q4 2026
- Submission of Phase 2 protocol early 2027
- Regulatory review by MHRA
Sectors affected
- Oncology
- Immunotherapy
- Pharmaceuticals
Regulatory implications
- Requirement for MHRA approval
- NHS cost‑effectiveness assessment
- Possibility of fast‑track designation
Historical parallels
- Development of anti‑TNF biologics for rheumatology
- Use of GLP‑1 agonists for weight loss
- Early trials of checkpoint inhibitors
Sources
Open the full interactive case file on Beyond →